| Registry | NCT03702140 |
|---|---|
| Status | Unknown |
| Phase | Phase 2 |
| Study type | Interventional; randomized, parallel, masking: single, treatment |
| Enrollment | 90 (Estimated) |
| Sponsor | Shinshu University (Other) |
| Conditions | Osteoporosis |
| Interventions | "Teriparatide", "Forteo® or Teribon" (Drug) |
| Dates | start 2018-10-09, primary completion 2023-10-08 (estimated), completion 2025-10-08 (estimated), first posted 2018-10-10, last updated 2021-09-21 |
| Locations | 1 site in Japan |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Osteoporosis All trials of "Teriparatide", "Forteo® or Teribon"
The aim of this study is to examine the efficacy and adverse events in the following 3 groups in osteoporosis patients:
1. The administration period of teriparatide is less than 6 months and thereafter, denosumab for 24 months.
2. The administration period of teriparatide is from 6 to 12 months and thereafter, denosumab for 24 months.
3. The administration period of teriparatide is more than 12 months and thereafter, denosumab for 24 months.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| TPTD 6M | Active comparator | Drug: "Teriparatide", "Forteo® or Teribon" | |
| TPTD 6-12M | Active comparator | Drug: "Teriparatide", "Forteo® or Teribon" | |
| TPTD 12-24M | Active comparator | Drug: "Teriparatide", "Forteo® or Teribon" |
Sex: All, ages: 20 Years to 120 Years
Inclusion Criteria: * Osteoporotic patients who want to take teriparatide and denosumab Exclusion Criteria: * Patients who are allergic to teriparatide or denosumab Patients who are pregnant or breast-feedin
| Facility | City | Country | Status |
|---|---|---|---|
| Yukio Nakamura | Matsumoto, Nagano | Japan | Recruiting |